ResearcherThe University of SydneyNo recent work listed

Matteo Salvatore Carlino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7861-4104; OpenAlex author ID A5083061830. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2015: 1 paper

Papers 1

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Co-author DOI 10.1200/jco.2013.51.5783 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Georgina Venetia Long · 1 shared paper, 2015 · strength 0.05
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783 ↗
Desmond Yip · 1 shared paper, 2015 · strength 0.05
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783 ↗
Sean Michael Grimmond · 1 shared paper, 2015 · strength 0.05
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783 ↗
Adnan M. Nagrial · 1 shared paper, 2015 · strength 0.05
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783 ↗
Andrew Victor Biankin · 1 shared paper, 2015 · strength 0.05
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.